| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/19/2000 | EP0993613A2 Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumours originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma |
| 04/19/2000 | EP0993483A1 Conjugate of polyethylene glycol and chitosan |
| 04/19/2000 | EP0993337A1 Hydrophilic polymeric material and method of preparation |
| 04/19/2000 | EP0993305A2 Composition for enhanced uptake of polar drugs from mucosal surfaces |
| 04/19/2000 | EP0813396A4 Controlled dissolution pellet containing calcium sulfate |
| 04/19/2000 | EP0760679B1 Photodynamic conjugates with biocidal properties |
| 04/19/2000 | EP0741565B1 Process for producing s(+)-ibuprofen particles |
| 04/19/2000 | EP0652775B1 Targeting of liposomes to the blood-brain barrier |
| 04/19/2000 | EP0586520B1 Backbone modified oligonucleotide analogs |
| 04/19/2000 | EP0567528B1 Depot formulations |
| 04/19/2000 | EP0550561B1 Purification of cytokeratin fragments |
| 04/19/2000 | CN1251112A Cross-linked vinyl polymers with bile acid adsorbing effect |
| 04/19/2000 | CN1251111A Improvements relating to bran gels |
| 04/19/2000 | CN1251045A Gel delivery vehicles for anticellular proliferative agent |
| 04/19/2000 | CN1250669A Ion composite type water-soluble pharmaceutical compositions, and use thereof |
| 04/19/2000 | CN1250668A Stable protein compositions |
| 04/19/2000 | CN1250648A Cosmetics prepn. compositions |
| 04/18/2000 | USRE36665 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 04/18/2000 | US6051693 Human monoclonal antibody which preferentially binds to neoplastic cell over a normal cell of same tissue type; for diagnosis, anticarcinogenic agents and antitumor agents |
| 04/18/2000 | US6051686 Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| 04/18/2000 | US6051648 Crosslinked polymer compositions and methods for their use |
| 04/18/2000 | US6051567 Stable aqueous solution |
| 04/18/2000 | US6051558 Compositions suitable for controlled release of the hormone GnRH and its analogs |
| 04/18/2000 | US6051429 Peptide-enhanced cationic lipid transfections |
| 04/18/2000 | US6051410 Self-assembled, defective, nonself-propagating viral particles |
| 04/18/2000 | US6051405 An expression vector containing a dna segment that directs the synthesis of a recombinant fusion protein which is a single chain fab variable region from a modified pseudomonas exotoxin gene; producing improved toxins |
| 04/18/2000 | US6051387 Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies |
| 04/18/2000 | US6051259 Composition for sustained release of human growth hormone |
| 04/18/2000 | US6051258 Proteinoid emulsions and methods for preparation and use thereof |
| 04/18/2000 | US6051255 Polymer coated tablet comprising amoxycillin and clavulanate |
| 04/18/2000 | US6051252 Compacted ribavirin composition substantially free of other ribavirin polymorphic forms. |
| 04/18/2000 | US6051250 Process for the stabilization of vesicles of amphiphilic lipid(s) and composition for topical application containing the said stabilized vesicles |
| 04/18/2000 | US6051245 Water soluble polymer composition for use as thickeners/stabilizers for products for topical application such as personal care products for application to skin or hair, or topically administrable pharmaceutical preparations |
| 04/18/2000 | US6051244 Treating skin aging by topically applying to affected skin areas fructose 1,6-diphosphate or its salts or mixtures to inhibit loss of elastic and collagen fibers in the dermis |
| 04/18/2000 | US6051239 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| 04/18/2000 | US6051238 Stabilizers for lyophilized mumps vaccines |
| 04/18/2000 | US6051237 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| 04/18/2000 | US6051230 For treatment and/or diagnosis (imaging) of vascularized solid tumors |
| 04/18/2000 | US6051229 Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions |
| 04/18/2000 | US6051225 Family of high affinity, modified antibodies for cancer treatment |
| 04/18/2000 | US6051223 Mixing with anionic polymer, acid, amine or their salts |
| 04/18/2000 | US6051221 BRK protein tyrosine kinase and encoding nucleic acid |
| 04/18/2000 | US6051207 Phosphatidylserine linked isoxazole sulfonamide derivatives; diagnosing and imaging cardiovascular disorders |
| 04/18/2000 | CA2137297C Reactive vesicle and functional substance-fixed vesicle |
| 04/18/2000 | CA2124553C Pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times |
| 04/18/2000 | CA2069485C Delayed release formulations |
| 04/18/2000 | CA2009570C Electrotransport adhesive |
| 04/13/2000 | WO2000061108A1 Pharmaceutical aerosol formulation |
| 04/13/2000 | WO2000020642A1 Prevention of adhesions |
| 04/13/2000 | WO2000020625A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 04/13/2000 | WO2000020556A2 Zinc finger-reactive antimicrobial compounds |
| 04/13/2000 | WO2000020043A1 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers |
| 04/13/2000 | WO2000020038A1 Method of treating prostate cancer with an adenovirus vector |
| 04/13/2000 | WO2000020036A1 Pharmaceutical compositions containing paclitaxel |
| 04/13/2000 | WO2000020035A1 Oxybutynin formulations and methods of use |
| 04/13/2000 | WO2000020031A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 04/13/2000 | WO2000020007A1 Method and compositions for increasing bone mass |
| 04/13/2000 | WO2000020000A1 Controlled release oral preparations of esculetin and its derivatives |
| 04/13/2000 | WO2000019996A1 Controlled drug release system of retinoic acid |
| 04/13/2000 | WO2000019990A2 Rar antagonists as male anti-fertility agents |
| 04/13/2000 | WO2000019987A1 Mucosal originated drug delivery systems and animal applications |
| 04/13/2000 | WO2000019985A2 New sustained release oral formulations |
| 04/13/2000 | WO2000019984A2 Coated medicament forms with controlled active substance release |
| 04/13/2000 | WO2000019982A1 Spray coated microparticles for use in needleless syringes |
| 04/13/2000 | WO2000019981A1 Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide |
| 04/13/2000 | WO2000019980A1 Glucoside paucilamellar vesicles |
| 04/13/2000 | WO2000019979A1 Foamable formulation and foam |
| 04/13/2000 | WO2000019978A2 Compositions and methods for enhancing receptor-mediated cellular internalization |
| 04/13/2000 | WO2000019976A2 Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them |
| 04/13/2000 | WO2000019963A1 Capsules |
| 04/13/2000 | WO2000000224A3 Method for transporting a molecular substance in predetermined areas of eucaryotic cells |
| 04/13/2000 | WO1999065462A3 Use of aminosterol derivatives as chloride ionphores |
| 04/13/2000 | WO1999058151A3 Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells |
| 04/13/2000 | WO1999055720A9 Targeted gene delivery to cells by filamentous bacteriophage |
| 04/13/2000 | WO1999055345A9 Combination viral-based and gene-based therapy of tumors |
| 04/13/2000 | WO1999051265A9 Nucleic acid encoding hyaluronan synthase and methods of use |
| 04/13/2000 | CA2354863A1 Prevention of adhesions |
| 04/13/2000 | CA2346687A1 Use of rar antagonists or inverse agonists as male anit-fertility agents |
| 04/13/2000 | CA2346459A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 04/13/2000 | CA2346456A1 Method and compositions for increasing bone mass |
| 04/13/2000 | CA2346332A1 Oxybutynin formulations and methods of use |
| 04/13/2000 | CA2346326A1 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers |
| 04/13/2000 | CA2346048A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 04/13/2000 | CA2345945A1 Spray coated microparticles for use in needleless syringes |
| 04/13/2000 | CA2345808A1 Mucosal originated drug delivery systems and animal applications |
| 04/13/2000 | CA2345729A1 Pharmaceutical compositions containing paclitaxel |
| 04/13/2000 | CA2345240A1 Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them |
| 04/13/2000 | CA2345212A1 Zinc finger-reactive antimicrobial compounds |
| 04/13/2000 | CA2285818A1 Composition to enhance skin permeation of topical skin agents |
| 04/12/2000 | EP0992579A1 Stem cell factor |
| 04/12/2000 | EP0992489A1 Betaines |
| 04/12/2000 | EP0992237A2 Neohesperidine dc as cristallisation inhibitor |
| 04/12/2000 | EP0992235A1 Cometic composition |
| 04/12/2000 | EP0991427A2 Improvements in or relating to diagnostic/therapeutic agents |
| 04/12/2000 | EP0991417A1 Complex formation between dsdna and oligomer of heterocycles |
| 04/12/2000 | EP0991415A1 Orally administrable solid ribavirin dosage forms and process for making them |
| 04/12/2000 | EP0991409A1 Controlled release pharmaceutical compositions containing tiagabine |
| 04/12/2000 | EP0991408A1 Novel process for manufacturing paroxetine solid dispersions |
| 04/12/2000 | EP0991407A2 Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations |
| 04/12/2000 | EP0991405A1 Clear, injectable formulation of an anesthetic compound |